MedPath
Found 10 clinical trials|View Analysis
Sort by:

ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74

Phase 1
Not yet recruiting
Conditions
Tuberculosis, Pulmonary
Interventions
Biological: QTP101
Biological: Placebo
First Posted Date
2024-12-03
Last Posted Date
2024-12-03
Lead Sponsor
Quratis Inc.
Target Recruit Count
144
Registration Number
NCT06714513
Locations
🇰🇷

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, Gyeonggi-do, Korea, Republic of

🇰🇷

Yonsei University Severance Hospital, Seoul, Korea, Republic of

🇰🇷

The Catholic University of Korea Seoul ST.MARY'S Hospital, Seoul, Korea, Republic of

and more 1 locations

ID93/GLA-SE Vaccination + BCG Challenge

Not Applicable
Not yet recruiting
Conditions
Tuberculosis
Interventions
Biological: ID93/GLA-SE
Biological: BCG Danish
First Posted Date
2024-11-01
Last Posted Date
2024-12-05
Lead Sponsor
University of Oxford
Target Recruit Count
48
Registration Number
NCT06670755
Locations
🇬🇧

Centre for Clinical Vaccinology and Tropical Medicine, Oxford, Oxfordshire, United Kingdom

Therapeutic ID93 + GLA-SE Vaccination in Participants with Rifampicin-Susceptible Pulmonary TB

Phase 2
Not yet recruiting
Conditions
Tuberculosis, Pulmonary
Interventions
Biological: Placebo vaccine
Biological: ID93 + GLA-SE vaccine
First Posted Date
2024-01-16
Last Posted Date
2024-12-13
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
1500
Registration Number
NCT06205589

Phase 1 Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Adolescent

Phase 1
Conditions
Tuberculosis
Interventions
Biological: ID93+GLA-SE
Biological: Placebo
First Posted Date
2019-01-16
Last Posted Date
2019-07-23
Lead Sponsor
Quratis Inc.
Target Recruit Count
36
Registration Number
NCT03806699
Locations
🇰🇷

HALLYM UNIV. Chuncheon Sacred Heart Hospital, Chuncheon, Korea, Republic of

Phase 2a Clinical Trial of ID93+GLA-SE Vaccine in BCG-vaccinated Healthy Healthcare Workers

Phase 2
Conditions
Tuberculosis
Interventions
Biological: ID93+GLA-SE
Biological: Placebo
First Posted Date
2019-01-16
Last Posted Date
2019-05-31
Lead Sponsor
Quratis Inc.
Target Recruit Count
107
Registration Number
NCT03806686
Locations
🇰🇷

Ajou University Hospital, Gyeonggi-do, Korea, Republic of

🇰🇷

Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

🇰🇷

Chung-Ang University Hospital, Seoul, Korea, Republic of

Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults

Phase 1
Completed
Conditions
Pulmonary TB
Interventions
Biological: ID93 + GLA-SE
First Posted Date
2018-10-29
Last Posted Date
2023-06-01
Lead Sponsor
Access to Advanced Health Institute (AAHI)
Target Recruit Count
48
Registration Number
NCT03722472
Locations
🇺🇸

Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States

Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects

Phase 1
Completed
Conditions
Tuberculosis
Interventions
Other: AP10-602
Biological: GLA-SE
Biological: ID93
First Posted Date
2015-07-24
Last Posted Date
2017-09-15
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
70
Registration Number
NCT02508376
Locations
🇺🇸

University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States

Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion

Phase 2
Completed
Conditions
Pulmonary Tuberculosis
Interventions
Biological: ID93 + GLA-SE
Other: Placebo
First Posted Date
2015-06-08
Last Posted Date
2019-03-12
Lead Sponsor
Access to Advanced Health Institute (AAHI)
Target Recruit Count
60
Registration Number
NCT02465216
Locations
🇿🇦

TASK Applied Sciences, Cape Town, South Africa

🇿🇦

Desmond Tutu HIV Centre (DTHC), Cape Town, South Africa

🇿🇦

South African Tuberculosis Vaccine Initiative (SATVI), Worcester, South Africa

Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers

Phase 1
Completed
Conditions
Pulmonary Tuberculosis
Interventions
Other: Placebo
Biological: ID93 + GLA-SE
First Posted Date
2013-08-22
Last Posted Date
2018-02-01
Lead Sponsor
Access to Advanced Health Institute (AAHI)
Target Recruit Count
66
Registration Number
NCT01927159
Locations
🇿🇦

SATVI, Worcester, Western Cape, South Africa

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Phase 1
Completed
Conditions
Pulmonary Tuberculosis
Interventions
Biological: ID93 + GLA-SE
Biological: ID93 alone
First Posted Date
2012-05-16
Last Posted Date
2017-09-15
Lead Sponsor
Access to Advanced Health Institute (AAHI)
Target Recruit Count
60
Registration Number
NCT01599897
Locations
🇺🇸

Johnson County Clin-Trials, Lenexa, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath